severe Severity

Wall Pellitory Allergy: The Mediterranean Pollen Powerhouse in California

Wall pellitory allergy is an IgE-mediated reaction to windborne pollen from Parietaria judaica, one of the most important pollen allergens in the Mediterranean basin, responsible for up to 80% of pollinosis in some Southern European populations. Four WHO/IUIS allergens are characterized, with Par j 2 serving as the species-specific marker at 73% of Parietaria-specific IgE. In the US, it grows in California and sporadically along the mid-Atlantic coast. Sublingual immunotherapy is well-established for Parietaria desensitization in European clinical practice.

severePeak: Febโ€“NovUpdated April 13, 2026

Free ยท 5 min ยท Insurance accepted

Reviewed by Dr. Chet Tharpe, M.D.
As seen inUSA TODAYMen's HealthCBSForbes
The numbers
Headline stat
~0%
PAR J 2 SPECIFIC IgE
US prevalence
0โ€“30%
Peak season
Febโ€“Nov
Symptoms tracked
0
Treatment paths
0
01Overview

What Is Wall Pellitory Allergy?

Wall pellitory allergy is an IgE-mediated respiratory allergy triggered by pollen from Parietaria judaica, a small, inconspicuous weed in the Urticaceae (nettle) family that grows on walls, rubble, dry masonry, and urban cracks.

Despite its modest appearance, wall pellitory is one of the most clinically significant pollen allergens in the world โ€” responsible for up to 80% of pollinosis in some Southern European populations and causing both severe rhinitis and asthma.

What makes Parietaria exceptional among weed pollen allergens is the combination of four WHO/IUIS-listed allergens, an extraordinarily long pollen season (February through November in mild climates), and high sensitization rates in exposed populations. In Italy and Spain, 20-30% of allergy patients are sensitized to Parietaria. This is one of the most thoroughly studied and well-understood pollen allergen systems in the world.

In the United States, Parietaria judaica is found in California โ€” particularly coastal and Southern California โ€” and sporadically around mid-Atlantic ports. It is almost certainly underrecognized in US allergy practice. Californian patients with chronic rhinoconjunctivitis spanning most of the year should be evaluated for Parietaria sensitization, particularly if they live in areas with Mediterranean climate and old masonry or stone walls.

02Symptoms

Wall Pellitory Allergy Symptoms

Recognizing symptoms early helps you get the right treatment faster.

Severe nasal congestion

severe

Intense bilateral nasal obstruction that may persist for months during the extended Parietaria pollen season, significantly impairing breathing and sleep.

Profuse rhinorrhea

moderate

Heavy watery nasal discharge that may require frequent tissue use throughout the day during peak pollen months.

Allergic conjunctivitis

moderate

Bilateral eye itching, redness, tearing, and lid swelling that can be severe enough to impair visual comfort and daily activities.

Asthma exacerbation

severe

Wheezing, chest tightness, cough, and dyspnea. Parietaria is specifically associated with severe asthma, not just rhinitis โ€” a clinical feature that elevates its severity rating.

Persistent sneezing

moderate

Repetitive sneezing bouts that may occur throughout the day during peak pollen production, particularly during outdoor activities near masonry structures.

Post-nasal drip

mild

Chronic mucus drainage from nasal passages causing throat irritation, frequent clearing, and a persistent cough that worsens at night.

Chronic fatigue

moderate

Months of continuous nasal obstruction and poor sleep from near-year-round symptoms produce significant fatigue, cognitive impairment, and mood changes.

Nasal polyps (with prolonged exposure)

severe

Chronic untreated Parietaria-driven nasal inflammation may promote polyp formation in susceptible individuals, further worsening obstruction.

When to see a doctor

Wall pellitory allergy is notable for its severity. In Mediterranean populations, Parietaria causes not just rhinoconjunctivitis but severe asthma โ€” a clinical profile that distinguishes it from many other weed pollens that primarily affect the upper airways. The nsLTP allergen profile (Par j 1, Par j 2) may contribute to this severity, as nsLTPs are associated with more severe allergic reactions across multiple allergen systems. The near-year-round symptom duration in mild climates can be debilitating. Patients may experience 10 months of continuous rhinitis, making it one of the most burdensome pollen allergies when untreated. If you live in California and experience chronic rhinoconjunctivitis that does not respond well to dust mite or mold treatment, Parietaria sensitization should be investigated. Anaphylaxis from Parietaria pollen inhalation is not typical, but severe asthma attacks requiring emergency care are documented in highly sensitized patients. Have an asthma action plan and rescue medication accessible if you have confirmed Parietaria-associated asthma.

Wall Pellitory and Severe Asthma

Wall pellitory is specifically associated with severe asthma, not just rhinoconjunctivitis. This distinguishes it from many other weed pollen allergens that primarily affect the upper airways. In Mediterranean populations, Parietaria-associated asthma represents a substantial portion of seasonal asthma cases, and the near-year-round pollen season means that "seasonal" asthma from Parietaria behaves more like persistent asthma in terms of airway inflammation duration. The association with severe lower airway disease may relate to the nsLTP allergen profile: lipid transfer proteins are known across multiple allergen systems for their ability to provoke more severe immune responses than other protein families. In California, Parietaria-sensitized patients with poorly controlled asthma that does not respond adequately to standard perennial allergen treatment should be specifically tested for Par j 2. Parietaria-driven bronchial inflammation is particularly concerning because the near-year-round pollen exposure can prevent the airway recovery periods that patients with shorter-season allergens experience during pollen-free months. This sustained inflammatory stimulus promotes subepithelial fibrosis and smooth muscle hypertrophy โ€” the hallmarks of airway remodeling that make asthma progressively harder to control. Pulmonary function monitoring with serial spirometry is recommended for Parietaria-sensitized asthma patients to track any decline in forced expiratory volume.

If left untreated

Complications of Untreated Wall Pellitory Allergy

The primary complication risk with untreated Parietaria allergy is the sheer duration of inflammation. Ten months of continuous nasal and bronchial exposure to a potent pollen allergen can drive disease progression that is more aggressive than typical seasonal allergies. Without treatment, the trajectory can move from intermittent rhinitis to chronic rhinosinusitis with polyps and from mild asthma to severe persistent asthma requiring intensive pharmacotherapy. Untreated Parietaria-driven inflammation over many months can also impair mucociliary clearance, increasing susceptibility to recurrent sinus infections that further compound the chronic nasal obstruction. Parietaria-sensitized patients who develop nasal polyps may require surgical polypectomy, though polyps frequently recur without concurrent immunotherapy to reduce the underlying allergic inflammation. The near-perennial inflammatory stimulus also increases the risk of developing sensitization to additional aeroallergens through the phenomenon of epithelial barrier disruption โ€” chronic nasal inflammation damages the mucosal barrier, allowing other inhaled proteins to penetrate and trigger new IgE responses. Sleep disruption from months of continuous nasal obstruction can contribute to daytime fatigue, impaired cognitive function, mood disturbance, and reduced academic or occupational performance that patients may not attribute to their allergy.

Chronic rhinosinusitis with nasal polyps

Near-year-round nasal inflammation from Parietaria pollen drives chronic eosinophilic inflammation that promotes nasal polyp formation, worsening obstruction and anosmia.

Severe persistent asthma

The extended pollen season creates a quasi-perennial lower airway inflammatory stimulus that can promote airway remodeling and progression to severe asthma.

Misdiagnosis as perennial allergy

The 10-month pollen season mimics perennial allergen exposure, potentially leading to misattribution of symptoms to dust mites or mold and inappropriate treatment targeting.

Significant quality-of-life impairment

Ten months of chronic symptoms affect work productivity, exercise tolerance, sleep quality, and mental health more profoundly than typical seasonal allergies.

03Why it happens

What Causes Wall Pellitory Allergy?

Parietaria judaica is wind-pollinated, releasing lightweight pollen grains across an extraordinarily long season โ€” February through November in mild climates, essentially most of the year. This extended production window distinguishes it from most weed pollens, which typically produce pollen for two to four months.

Common Species

Pellitory of the wall / wall pellitory

Parietaria judaica

Upright pellitory

Parietaria officinalis

Stinging nettle (related Urticaceae, different allergy profile)

Urtica dioica

Parietaria pollen proteins, particularly Par j 1 and Par j 2, are inhaled and processed by dendritic cells. Th2 lymphocytes drive IgE class-switching in B cells, producing Par j 2-specific IgE that binds to mast cell FcepsilonRI receptors in the respiratory mucosa. On re-exposure, cross-linking of surface IgE by Par j 2 triggers mast cell degranulation with histamine, leukotriene, and prostaglandin release, producing immediate-phase rhinoconjunctivitis and, in severely sensitized patients, bronchospasm. The high concentration of nsLTP allergens may contribute to the severity of lower airway symptoms.

Four WHO/IUIS allergens have been characterized: Par j 1 (nsLTP1, a major allergen), Par j 2 (nsLTP1, the species-specific marker allergen accounting for approximately 73% of Parietaria-specific IgE), Par j 3 (profilin, a pan-allergen), and Par j 4 (polcalcin, a pan-allergen). Both Par j 1 and Par j 2 are non-specific lipid transfer proteins, but critically, Par j 2 does NOT significantly cross-react with other nsLTPs such as Pru p 3 (peach) or Art v 3 (mugwort). This makes Par j 2 a species-specific marker that distinguishes genuine Parietaria sensitization from pan-allergen cross-reactivity.

A comparative study found that only 7% of non-Mediterranean patients showed genuine rPar j 2 reactivity, compared to 83% of Mediterranean patients. Most US positivity to Parietaria extract in non-Californian populations is likely driven by cross-reactive pan-allergens (profilin, polcalcin) rather than true Parietaria sensitization.

Who's most affected

Risk factors to watch for

01

Residence in coastal or Southern California

The Mediterranean climate of California provides ideal growing conditions for Parietaria judaica, and the plant is established in this region, particularly along walls, masonry, and urban cracks.

02

Mediterranean heritage or travel history

Patients who lived in or frequently visit Southern Europe (Italy, Spain, Greece, southern France) may have been sensitized abroad and experience symptoms in California.

03

Living near old masonry or stone structures

Parietaria grows preferentially on walls, rubble, dry masonry, and in urban cracks. Properties with old stone walls or masonry retaining walls may harbor the plant.

04

Atopic predisposition

Individuals with existing aeroallergen sensitivities are at higher risk of developing Parietaria sensitization when exposed to the pollen.

The Allergy Cascade

1.Exposure

Allergen contact

2.Detection

Immune recognition

3.IgE Response

Antibody production

4.Mast Cells

Histamine release

5.Symptoms

Allergic reaction

05Diagnosis

Diagnosing Wall Pellitory Allergy

Wall pellitory sensitization can be diagnosed through skin prick testing or serum-specific IgE (ImmunoCAP) for Parietaria judaica. Standardized Parietaria extracts are widely available in European allergy practice and accessible through US allergy laboratories. The critical diagnostic refinement is component-resolved diagnostics with rPar j 2, the species-specific marker allergen. Because only 7% of non-Mediterranean patients show genuine Par j 2 reactivity (versus 83% of Mediterranean patients), positive extract-based results in non-Californian US populations should be confirmed with Par j 2 testing to distinguish true Parietaria sensitization from pan-allergen cross-reactivity. At-home allergy testing services like Curex offer comprehensive panels covering 40+ common environmental allergens with results typically within 5 days and insurance coverage. Identifying Parietaria as a sensitizer alongside other weed, grass, and tree pollens guides comprehensive immunotherapy formulation โ€” particularly important given the extended treatment window that Parietaria requires.

Skin Prick Test with Parietaria Extract

Standardized Parietaria judaica pollen extract applied via skin prick. A positive wheal-and-flare confirms IgE sensitization. Widely available through allergy clinics.

Serum Specific IgE (ImmunoCAP for Parietaria)

Blood-based measurement of Parietaria-specific IgE. Quantitative results help assess sensitization level and guide immunotherapy dosing decisions.

Component-Resolved Diagnostics (rPar j 2)

Molecular-level IgE testing for Par j 2, the species-specific nsLTP marker that accounts for 73% of Parietaria-specific IgE. Distinguishes genuine Parietaria sensitization from profilin/polcalcin cross-reactivity.

At-home testing

Test from home with Curex

Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.

Take the allergy quiz
Insurance acceptedBoard-certified allergists
06Treatment

Treating Wall Pellitory Allergy

See how different approaches stack up for managing your allergy symptoms long-term.

Treatment of wall pellitory allergy benefits from decades of European clinical experience. Parietaria SLIT is one of the best-studied sublingual immunotherapy applications in the world, with extensive clinical trial data from Italian and Spanish allergy centers. The pharmacotherapy approach follows standard guidelines but must account for the near-year-round treatment duration required by the extended pollen season.

For patients in California with confirmed Par j 2 sensitization, comprehensive treatment should address both the Parietaria component and any co-existing aeroallergen sensitizations. The severity of Parietaria-associated asthma makes immunotherapy a particularly strong recommendation for this allergen. Combination therapy with an intranasal corticosteroid and an oral antihistamine is often necessary during peak pollen months, as single-agent pharmacotherapy may provide inadequate symptom control against the high-potency Parietaria pollen. Patients with confirmed Parietaria-associated asthma should also carry a rescue short-acting beta-agonist inhaler and may require an inhaled corticosteroid controller during the extended pollen season.

Allergen Avoidance

Identify and remove Parietaria plants from your property โ€” look for low-growing weeds with small oval leaves growing from masonry cracks, old walls, and rubble. Keep windows closed during the extended pollen season. Use HEPA air purifiers.

N/A

Helpful for reducing hyperlocal exposure; limited by the 10-month season and difficulty identifying all plant sources

Oral Antihistamines

Second-generation antihistamines for rhinoconjunctivitis symptoms. Given the extended season, daily use for up to 10 months may be required.

Cetirizine (Zyrtec), loratadine (Claritin), fexofenadine (Allegra)

Studies suggest 40-60% symptom reduction; may require combination with nasal steroids for adequate control

Intranasal Corticosteroids

First-line treatment for moderate-to-severe Parietaria rhinitis. The extended season may require near-year-round use in mild climates.

Fluticasone propionate (Flonase), mometasone (Nasonex), budesonide (Rhinocort)

Most effective single agent for nasal symptoms; clinical trials in Parietaria-sensitized patients demonstrate significant improvement

Subcutaneous Immunotherapy (SCIT)

Traditional allergy shots with Parietaria extract. Well-validated in European clinical practice with extensive long-term efficacy data.

Parietaria pollen extract, custom-formulated with additional allergens as needed

European studies demonstrate 60-80% symptom reduction with sustained benefit after treatment completion

Sublingual Immunotherapy (SLIT)

Parietaria SLIT is one of the best-studied SLIT applications in the world, with extensive clinical trial data from European allergy centers. Custom-formulated drops for at-home daily use.

Custom sublingual drops including Parietaria and other confirmed allergens

European clinical evidence demonstrates 60-85% symptom reduction; among the strongest SLIT evidence bases for any allergen

Traditional

  • NoTreats root cause
  • NoLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • YesLow side effects
  • PartialEstimated cost

Allergy Shots (SCIT)

  • YesTreats root cause
  • YesLong-lasting relief
  • NoAt-home treatment
  • NoNo office visits
  • PartialLow side effects
  • PartialEstimated cost

Immunotherapy (SLIT)

Recommended
  • YesTreats root cause
  • YesLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • YesLow side effects
  • YesEstimated cost
Immunotherapy

Immunotherapy for Wall Pellitory Allergy

Instead of masking symptoms, immunotherapy retrains your immune system.

Parietaria immunotherapy has one of the strongest evidence bases of any SLIT application worldwide. Italian and Spanish allergy centers have conducted numerous clinical trials demonstrating significant and sustained symptom reduction, decreased medication requirements, and improved quality of life in Parietaria-sensitized patients treated with sublingual immunotherapy. This makes wall pellitory allergy one of the best SLIT indications in this entire collection. The severity of Parietaria-associated asthma and the near-year-round symptom burden make immunotherapy particularly compelling for this allergen. Ten months of daily pharmacotherapy year after year is the alternative โ€” immunotherapy offers the prospect of lasting immune tolerance that persists after the 3-5 year treatment course. Sublingual immunotherapy, offered by providers like Curex, delivers custom-formulated allergen drops under the tongue at home, with plan-specific pricing (https://getcurex.com/learn/curex-pricing); insurance accepted for testing and consultations. For Californian patients with confirmed Par j 2 sensitization, Parietaria-inclusive SLIT draws on one of the deepest evidence pools in all of weed pollen immunotherapy. Most patients experience meaningful symptom improvement within the first season, with sustained benefit achieved after three to five years. In a real-world Curex study of 2,897 patients on at-home sublingual immunotherapy (Tharpe et al., Frontiers in Allergy, 2026), clinically meaningful symptom improvement rose to 45% of patients by two years and quality-of-life improvement reached 90.7%, with adherence over 90% and no anaphylaxis reported.

1Step 1

Confirm Parietaria Sensitization

Undergo IgE testing including rPar j 2 component testing to confirm genuine Parietaria sensitization versus pan-allergen cross-reactivity.

2Step 2

Comprehensive SLIT Formulation

An allergist creates a sublingual drop formula including Parietaria and all other confirmed aeroallergen sensitizations for comprehensive treatment.

3Step 3

Daily At-Home Administration

Place drops under the tongue daily. Parietaria SLIT is among the best-validated SLIT protocols in the world, with decades of European clinical experience.

4Step 4

Lasting Disease Modification

After 3-5 years, sustained immune tolerance reduces symptoms and medication needs even after treatment discontinuation โ€” transforming the 10-month annual burden.

โ€œEuropean clinical trials demonstrate 60-85% symptom reduction for Parietaria SLIT โ€” among the strongest evidence bases for any weed pollen immunotherapyโ€

Curex drops

Treat your Wall Pellitory allergy at the source

See if at-home sublingual allergy drops fit your allergies โ€” a 2-minute quiz, designed by board-certified allergists, with no needles and no clinic visits.

  • MD-led
    Board-certified allergists
  • Plan-specific
    Pricing ยท Confirm your quote
  • 50K+
    Patients treated
  • HSA/FSA
    Eligible
Living with it

Living With Wall Pellitory Allergy

Living with wall pellitory allergy in California means managing a near-year-round pollen allergen in one of the most favorable climates for outdoor living. The tension between California's outdoor lifestyle and the need for pollen avoidance makes immunotherapy particularly valuable โ€” it offers the prospect of enjoying the California climate without the 10-month respiratory burden. For patients who have recently moved to California from non-Mediterranean regions, the development of new-onset chronic rhinoconjunctivitis that does not match typical seasonal patterns should prompt consideration of Parietaria sensitization. Similarly, patients with Mediterranean heritage who experience chronic symptoms in California may be carrying a sensitization acquired in Europe.

  • Request Par j 2 Testing

    If you live in California and have chronic rhinoconjunctivitis that spans most of the year, ask your allergist about Parietaria-specific testing with Par j 2 component-resolved diagnostics. This allergen is likely underrecognized in US practice.

  • Survey Your Property for Parietaria

    Check old walls, masonry, stone retaining walls, and urban cracks for low-growing weeds with small oval leaves. Removing Parietaria plants from your immediate environment reduces hyperlocal pollen exposure.

  • Invest in Immunotherapy Early

    The 10-month annual symptom burden makes Parietaria one of the strongest SLIT indications. Starting immunotherapy early in your disease course provides the best prospect for sustained disease modification.

  • Connect with European Clinical Experience

    Parietaria immunotherapy has decades of evidence from Italian and Spanish allergy centers. If your US allergist is unfamiliar with Parietaria management, European clinical guidelines can provide helpful reference points.

When Is Wall Pellitory Pollen Season?

Wall pellitory has one of the longest pollen seasons of any allergen โ€” February through November in mild Mediterranean climates, essentially a 10-month production window. In California, where winter temperatures rarely drop to freezing in coastal areas, the season may extend nearly year-round in favorable microclimates. This extraordinary season length means that Parietaria-sensitized patients may experience symptoms that feel perennial rather than seasonal, potentially leading to misdiagnosis as perennial allergic rhinitis (dust mite, mold) when the actual driver is an outdoor pollen with an unusually long window. Peak pollen production typically occurs in spring (March-May) and again in late summer (September-October), creating a bimodal peak pattern within the extended season. However, significant pollen can be detected in any month from February through November in mild climates. In inland California valleys, where summer temperatures are higher and humidity is lower, Parietaria growth and pollen production may slow during the driest months before rebounding with fall moisture. Urban heat island effects in cities like Los Angeles may further modify the local pollen calendar, sometimes shifting peak production earlier in spring.

Spring

February - May

high intensity

Summer

June - August

medium intensity

Fall

September - November

high intensity

Preventing Wall Pellitory Allergy Reactions

Prevention strategies for wall pellitory allergy must account for the near-year-round pollen season. Standard seasonal precautions applied for two to three months are insufficient โ€” the vigilance window extends to ten months in mild California climates. This extended burden reinforces the case for immunotherapy as a disease-modifying intervention. Unlike most weed pollen allergens where avoidance measures can be concentrated into a brief seasonal window, Parietaria management requires sustained environmental controls that approach the year-round vigilance typically associated with perennial allergens like dust mites or pet dander. Patients should develop a comprehensive prevention plan at the start of each year rather than reacting to symptoms as they arise.

Identify and Remove Parietaria Plants

Look for low-growing weeds with small, oval, untoothed leaves growing from masonry cracks, stone walls, rubble, and dry urban surfaces. Remove plants before they flower to reduce hyperlocal pollen exposure.

Maintain HEPA Filtration Year-Round

In mild California climates, Parietaria pollen may be present from February through November. Run HEPA air purifiers in bedrooms continuously during this extended window.

Keep Windows Closed During Pollen Season

The extended pollen window means windows should remain closed for most of the year in areas with Parietaria growth. Use air conditioning with clean filters for ventilation.

Shower After Outdoor Activities

Rinse pollen from hair and skin after spending time outdoors, particularly in urban areas with old masonry where Parietaria grows abundantly.

Pursue Immunotherapy for Long-Term Prevention

Given the 10-month annual symptom burden, immunotherapy offers the best ratio of investment to long-term benefit for Parietaria-sensitized patients.

Long-term outlook

Long-Term Outlook for Wall Pellitory Allergy

The long-term outlook for wall pellitory allergy is highly favorable with appropriate treatment. Parietaria SLIT is among the most evidence-supported immunotherapy applications in the world, with decades of European clinical trial data demonstrating lasting disease modification. Climate change may expand Parietaria's US range beyond California, making early recognition and treatment increasingly important.

What to expect

Key takeaways

01

Wall pellitory is one of the most clinically significant pollen allergens globally, responsible for up to 80% of pollinosis in some Mediterranean populations.

02

Par j 2 is the species-specific marker allergen โ€” it does NOT cross-react with other nsLTPs, enabling definitive diagnosis of genuine Parietaria sensitization.

03

Parietaria SLIT has one of the strongest evidence bases of any allergen-specific immunotherapy, drawing on decades of Italian and Spanish clinical research.

04

In the US, this allergen is likely underrecognized โ€” Californian patients with chronic near-year-round rhinoconjunctivitis should be specifically evaluated.

Diet

Diet and Wall Pellitory Allergy

Despite Parietaria's nsLTP allergen profile (Par j 1, Par j 2), clinically significant food cross-reactivity is limited. Par j 2 does NOT significantly cross-react with other nsLTPs such as Pru p 3 (peach) or Art v 3 (mugwort) โ€” it is a species-specific marker. This distinguishes Parietaria from mugwort, where Art v 3 drives the mugwort-peach food allergy association. Patients with Parietaria sensitization who also experience oral allergy symptoms with fruits should be evaluated separately for primary food sensitization rather than assuming Parietaria cross-reactivity. An anti-inflammatory dietary pattern rich in omega-3 fatty acids from fish, flaxseed, and walnuts may help modulate baseline mucosal inflammation during the extended pollen season. Quercetin-rich foods such as onions, berries, and capers have demonstrated modest mast cell-stabilizing properties in preliminary studies and may complement standard pharmacotherapy, though they should not replace prescribed medications.

Foods that help

  • Omega-3-rich fish

    Anti-inflammatory fatty acids may help modulate baseline airway inflammation during the extended pollen season.

  • Vitamin C-rich foods (citrus, bell peppers)

    Natural antihistamine properties may complement pharmacotherapy during peak pollen months.

Par j 2's critical property is what it doesn't do โ€” it does not cross-react with peach LTP or mugwort LTP, making it a species-specific marker that distinguishes genuine Parietaria sensitization from the pan-allergen cross-reactivity that dominates most non-Mediterranean populations. In a California patient with a 10-month allergy season, Parietaria should always be on the differential.

Board-certified allergist (clinical reviewer for this article)
FAQ

Frequently Asked Questions

Wall pellitory (Parietaria judaica) is established in California, particularly coastal and Southern California, and has been found sporadically around mid-Atlantic ports. Climate change may expand its US range into other mild-climate regions. If you live in a Mediterranean-climate area of the US and have chronic rhinoconjunctivitis, Parietaria sensitization is worth investigating even if the plant has not been formally documented in your specific location. If you live in a warm, humid coastal area outside California and have unexplained year-round rhinitis, asking your allergist about Parietaria testing is worthwhile even if the plant is uncommon in your immediate area.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.

Get started today

Ready to treat your Wall Pellitory allergies for good?

Get a personalized treatment plan from board-certified allergists, delivered to your door.

Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.

Compare Curex plan pricing
3-minute quizBoard-certified allergistsProgram-specific pricing ยท Confirm your written quote

Questions about Curex itself?

Straight answers about the company, the evidence, what patients report, and what it costs โ€” including the parts that are not flattering.

Find out what you're actually allergic to โ€” and treat the cause

Take the free allergy quiz

Ready to treat your allergies at the source?

Take the free allergy quiz to find out if immunotherapy is right for you and get started with personalized treatment today.

Take Free Allergy Quiz